NY-AQARA
27.2.2024 14:01:39 CET | Business Wire | Press release
Aqara, a leading provider of smart home solutions, is excited to initiate the crowdfunding campaign for its latest home access solution, the Smart Lock U200, on Kickstarter. Designed for flexibility, convenience and security, the U200 lock is built upon the latest Thread protocol and natively Matter-enabled, aiming for effortless integration with the widest range of smart home devices across systems and brands1.
At its core, the Aqara U200 utilizes modern engineering crafted to provide users with numerous secure access options, ranging from fingerprints, one-time and recurring PIN codes, remote access via mobile apps, voice assistant commands to Aqara NFC cards and physical keys. Aqara is also working to add the HomeKey support to the U200 lock, which allows iOS users to unlock by simply tapping a compatible iPhone and Apple Watch. The U200 will be one of the first Matter-compatible locks to support HomeKey unlocking, and the Aqara team is sparing no time on developing and testing before delivering the optimized experiences2.
The U200 features a retrofit design, allowing for hassle-free installation on existing doors - without the need for extensive modification or renovation. Compatible with most doors in both Europe and North America, it attaches to existing lock mechanisms such as European cylinders (emergency function required) and deadbolts using one of the provided adapters3. The U200 intends to bring the modern keyless lifestyle to a broad array of homeowners and renters, while preserving the option to use traditional keys. Users also enjoy easy access sharing, remote access control, and real-time lock status updates for enhanced convenience and security.
The U200 lock runs on rechargeable Li-Ion batteries, while its wireless keypad can either be powered by a pack of four AAA batteries or wired to the existing doorbell wire (12V-24V DC power supply). Thanks to the power-efficient Thread protocol, the U200 lock features a battery life of up to 6 months between each charge4. Moreover, the wireless keypad boasts an IPX5 rating and withstands extreme heat and cold (-18℃/0℉ to 66℃/151℉), ensuring endurance under any climate.
As an integral part of a connected home, the U200 smart lock seamlessly works with other smart home accessories, allowing users to create a fully automated and customized smart home experience. For example, to disarm the home security system automatically when the U200 is unlocked by a family member, or to activate the indoor camera and the video doorbell after consecutive failed attempts to unlock the door. With three color options available for pre-order on Kickstarter, the U200 can fit into most home decor, making it the perfect addition to any home.
The Aqara Smart Lock U200 is now available for pre-order on Kickstarter at https://www.kickstarter.com/projects/aqara-u200/smartlock for those looking to be among the first to explore the latest in home access technologies.
- The U200 can be paired to the Aqara Home app using Bluetooth or the upcoming Aqara Hub M3. Compatibility with third-party Matter-enabled platforms (e.g., Amazon Alexa, Apple Home, Google Home, Samsung SmartThings, Home Assistant) is expected to roll out in waves, and may not be available by the shipment of pre-ordered units.
- HomeKey unlocking support is currently under development, and is expected to become available via a subsequent OTA update after the lock receives certain certification.
- Limitation applies. Please check the Kickstarter page or consult Aqara support for detailed guidelines on the U200 lock compatibility.
- The 6-month battery life is based on the assumption of 8 cycles of fingerprint/NFC unlocking and locking per day.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227373928/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom